| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| ln Vitro |
FIP22 (0.02-10 μM, 0-48 h) can induce rapid and persistent degradation of IRAK4 protein in HEK293T cells, but does not induce degradation of CRBN substrates or IRAK isoforms [1]. FIP22 (0.02-2 μM) can inhibit phosphorylation of key proteins in the LPS-induced NF-κB and MAPK signaling pathways in THP-1 cells and reduce the secretion of pro-inflammatory cytokines IL-6, TNF-α and chemokine CXCL8 [1]. FIP22 (120 μM) does not induce cytotoxicity in four normal cell lines (HEK293T, H2C9, BRL-3A, LO2) [1].
|
|---|---|
| ln Vivo |
FIP22 (10-30 mg/kg, intraperitoneal injection, once daily for 25 days) showed significant therapeutic effects in a 2,4-dinitrochlorobenzene (DNCB)-induced atopic dermatitis model [1].
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: THP-1 cells Tested Concentrations: 0.625, 1.25, 2.5 and 5 μM Incubation Duration: 24 h Experimental Results: Had no effect on the levels of IKZF1, IKZF3 and GSPT1. Did not induce degradation of other IRAK family subtypes, providing additional evidence for its target-specific effects. |
| Animal Protocol |
Animal/Disease Models: DNCB-induced atopic dermatitis (AD) model established in male BALB/c mice (8 weeks old)[1]
Doses: 10 and 30 mg/kg Route of Administration: Intraperitoneal injection (i.p.), every daily for 25 days Experimental Results: significantly improved skin lesions, including erythema, excoriation, scaling and crusting. No obvious systemic toxicity or weight loss. Significantly reduced the number of scratching times in mice. Reduced splenomegaly and reversed epidermal hyperplasia (thickening), hyperkeratosis, and inflammatory cell infiltration in the dermis. |
| References |
| Molecular Formula |
C46H50N10O6
|
|---|---|
| Molecular Weight |
838.95
|
| CAS # |
3091132-73-6
|
| Appearance |
Typically exists as solids at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1920 mL | 5.9598 mL | 11.9197 mL | |
| 5 mM | 0.2384 mL | 1.1920 mL | 2.3839 mL | |
| 10 mM | 0.1192 mL | 0.5960 mL | 1.1920 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
